Skip to main content

NEGEDIA

Research and Innovation

NEGEDIA

An outstanding developer of laboratory protocols and algorithms for NGS analysis.

The aim is to be able to transfer its technological know-how into the field of diagnostics. To be successful in doing this, Negedia must understand the needs of the clinic, which are often far away from NGS and from the huge potential knowledge gained from it.



PRECISIONS MEDICINE

NEGEDIA products aim to offer useful, accurate, complete and timely results designed to support the clinician in the diagnosis and management of the patient.

This is why NEGEDIA is constantly working on an ambitious R&D plan to create and optimize diagnostic solutions that are finally becoming accessible. The core of this innovation is to provide as many people as possible with their molecular and genetic information with clear clinical utility, following the logic of a medicine tailored to the intrinsic characteristics of each individual or their disease, with personalized approaches to wellness, prevention and treatment.

To do this, it is necessary to translate the most advanced Next Generation Sequencing (NGS) methods into clinical practice and screening, and to widely spread an innovative model of precision medicine.



NEGEDIA PATHOLOGY

The new frontier in molecular pathology.

Thanks to extensive research and development, Negedia has implemented an innovative transcriptomics protocol applied to molecular pathology samples of breast cancer: the Negedia Pathology Breast. Thanks to this method, it is possible to identify the molecular characteristics of a tissue, even if it is degraded or very old (e.g. FFPE; liquid biopsies).

The advantage over classical methods is that Negedia Pathology pushes the envelope of precision medicine in which the analysis of markers, including multigenic ones, makes it possible to prognosticate, diagnose and thus predict eligibility for current and new precision medicine treatment options.

For the specific case of breast cancer, the Negedia Pathology Breast with its proprietary and patented algorithm presents a result of immediate clinical utility, presenting the characterisation of the molecular subtype and reporting a level of expression of individual markers with negative-positive thresholds. The Negedia Pathology Breast is in continuity with current guidelines (AIOM 2019, ESMO 2022) and thus with the classical immunohistochemistry methodology, but at the same time has a high potential towards new precision medicine approaches.

Negedia is constantly working alongside Oncologists and Hospitals to support the development of new tissue analysis approaches based on Negedia Pathology.

GRANTS

CLICK ON LOGOS FOR MORE INFORMATIONS

CONTACT US

If you need more information about our products and services